Prices of cancer, cardiac, hepatitis, and arthritis could go down in India in the wake of the budget proposals of Monday.
The federal Finance Minister announced lowering of customs duty on as many as nine specified drugs, mainly biologics, used in treatment of cancer, HIV, hepatitis-B, arthritis drugs and two life-saving cardiac devices.
Advertisement
The reduction ranges from ten per cent to five per cent on medicines and bulk drugs, and from 7.5 per cent to five per cent on devices.
Also, Piramal healthcare Director Swati Pirmal noted, "Excise duty remaining at four per cent and implementation of GST should reduce transaction costs, and the patients should stand to benefit ultimately."
![Indian Finance Minister Increases Allocation for Health by 15 Per Cent]( "Indian Finance Minister Increases Allocation for Health by 15 Per Cent")
Presenting the budget for 2008-09 India's Finance Minister has increased the allocation for health by 15 percent, to Rs.165.34 billion, with stress on stress on HIV/AIDS, polio and healthcare.
However, the pharmaceutical and healthcare industry expressed their disappointment, saying their demands for tax incentives for R&D have been ignored. "The pharma industry has neither gained anything and nor lost anything in the Budget, there is nothing in it for us to celebrate," said Indian Drug Manufacturer Association Executive Director Gajanan Wakankar.
Fortis Healthcare Managing Director and Chief Executive Officer Shivinder Mohan Singh said, "Healthcare sector has been ignored. We had been expecting a boost for the healthcare infrastructure, but nothing has been said on it. Budget was mute.
We are disappointed."
However, reduction of customs duty and zero excise duty on certain medical device is likely to rationalize the cost of treatment of heart ailments. The devices are generally expensive for a large size population suffering from heart ailments in India, and hence rationalization should make the devices that much cheaper, said Ernst & Young Partner and National Leader, Health Sciences Practice, Hitesh Sharma said.
Source: Medindia
GPL
Indian Finance Minister Increases Allocation for Health by 15 Per Cent
Presenting the budget for 2008-09 India's Finance Minister has increased the allocation for health by 15 percent, to Rs.165.34 billion, with stress on stress on HIV/AIDS, polio and healthcare.
Advertisement
However, the pharmaceutical and healthcare industry expressed their disappointment, saying their demands for tax incentives for R&D have been ignored. "The pharma industry has neither gained anything and nor lost anything in the Budget, there is nothing in it for us to celebrate," said Indian Drug Manufacturer Association Executive Director Gajanan Wakankar.
Fortis Healthcare Managing Director and Chief Executive Officer Shivinder Mohan Singh said, "Healthcare sector has been ignored. We had been expecting a boost for the healthcare infrastructure, but nothing has been said on it. Budget was mute.
We are disappointed."
However, reduction of customs duty and zero excise duty on certain medical device is likely to rationalize the cost of treatment of heart ailments. The devices are generally expensive for a large size population suffering from heart ailments in India, and hence rationalization should make the devices that much cheaper, said Ernst & Young Partner and National Leader, Health Sciences Practice, Hitesh Sharma said.
Source: Medindia
GPL
Indian Pharma Market Posts Robust Growth
Never mind the global turbulence. India's pharma sector posted a robust growth of 14 per cent in September. In fact the domestic market has sustained its growth over the last year, at 15 per cent.
Advertisement
Advertisement
|
Advertisement
Recommended Readings
Latest Corporate News
The first World Health Organisation (WHO)/ International Labour Organisation (ILO) joint global monitoring report shows that more action is needed to ensure healthier, safer, more resilient, and more social workplaces.
Successful career transitions could be possible when people leverage their existing skills in the new occupation. A new Artificial Intelligence tool helps employees figure out the right job according to their current skill set.
AI and big data rule the pharmaceutical sector by enhancing the drug development process and increasing the marketing and sales of drugs
Insurance companies in the US are working towards adding food to their coverage menu to improve the people's health under their coverage and cut hospital costs.
Pharmaceutical companies need to make strategic decisions that will provide financial benefit while showing strong commitment to global health and their patients during the pandemic.